A Study of Daratumumab
A Phase 3b, Multicenter, Open-label, Daratumumab Long-term Extension Study
Janssen Research & Development, LLC
500 participants
Dec 15, 2022
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to provide ongoing access to study treatments for participants with multiple myeloma or smoldering multiple myeloma benefiting from treatment in certain Janssen Research and Development (R\&D) studies that use daratumumab as part of the study treatment regimen: access for all participants regardless of treatment group in daratumumab studies and access to participants in daratumumab-containing arms in the non-daratumumab studies will be allowed from studies which have reached clinical cutoff for final analysis. Certain long-term safety data will continue to be collected from study participants.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Daratumumab will be administered either intravenously or subcutaneously.
Carfilzomib will be administered intravenously.
Dexamethasone will be administered either orally or intravenously.
Lenalidomide will be administered orally.
Pomalidomide will be administered orally.
Locations(91)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT05438043